Dermatology

The effect of acne is more than skin deep.

Meena Julapalli, MD, notes the sessions she is most looking forward to at the Society for Pediatric Dermatology in Indianapolis, Indiana.

Tips for using patient education to help reduce the risk of postinflammatory hyperpigmentation.

At the 2022 Maui Derm NP+PA meeting in Colorado Springs, Colorado, a discussion of the newest biologics and how to "mix and match" medications and algorithms.

James Treat, MD, dives into pediatric patients dealing with alopecia areata, sleep issues in children with atopic dermatitis, and more.

Dr. Arkin speaks to how the psychological burdens of vitiligo can be exacerbated in younger patients, and what anticipated approvals such as ruxolitinib cream could mean for pediatric populations.

New data from ECZTRA 6 show improved sleep quality, itch relief and quality of life among teenagers treating atopic dermatitis with the IL-13 inhibitor.

Recent meta-analysis takes a look at possible adverse effects of the acne medicine, their frequency, and severity.

Robert Dracker, MD, MHA, MBA, CPI, discussed considerations and developmentally appropriate interventions to promote high quality, patient-centered pediatric infusion care in a presentation at the 2022 National Infusion Center Association Annual Conference.

At the 2022 SDPA Annual Summer Meeting, Lisa Swanson, MD, shared some fascinating patient presentations in pediatric dermatology.

A recent study showed that patients with atopic dermatitis have a higher prevalence of infertility, highlighting the need for clinicians to be wary of this increased risk and improve the care and management of this patient population.

Amy Paller, MD, sits down to answer important questions on the FDA approval of dupilumab for patients aged 6 months to 5 years.

Isotretinoin prescriptions are a challenging endeavor, requiring collaboration between providers, office administrative staff, pharmacists, insurance companies, and laboratory facilities.

Sanofi and Regeneron Pharmaceuticals, Inc announced the FDA approval of dupilumab. It is now the first biologic medicine for children from 6 months to 5 years old with moderate to severe atopic dermatitis.

Investigators explore the effectiveness of new combination therapies to address the multifactorial pathophysiology of acne vulgaris.

Understanding the difference in biology and clinical presentations of cutaneous conditions in different skin types is critical for health care professionals to treat a diverse population.

Learn to discern the best pain-mitigation strategies for each patient, based on research and personal experience.

Verrica received a Complete Response Letter from the FDA regarding their New Drug Application for the topical molluscum contagiosum treatment, VP-102.

A single lesson made an impact on high school students' knowledge and behavior when it came to sun protection.

Protection from the harsh rays of the sun is crucial for everyone—including children. Now that summer has arrived, a refresher course for your patients and their families on sun protection, which can go a long way in preventing skin damage and disorders due to the sun.

A 5-year-old nonverbal boy with autism spectrum disorder and global developmental delay presented to the emergency department with bilateral lower-extremity bruising and progressive difficulty ambulating. What's the diagnosis?

A look at the common condition and how to treat it.

For years, teenagers have been told to avoid certain foods to reduce acne. A review article examines the evidence.

Allergic contact dermatitis and atopic dermatitis are common causes of rashes in the pediatric population. Patch testing can help demystify the cause of such skin conditions and determine treatment.

A clinician updates the conventional wisdom on acne’s variations in patients of color, offering pearls from her practice and practical takeaways from recent research.